Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,500,668
  • Shares Outstanding, K 127,389
  • Annual Sales, $ 8,090 K
  • Annual Income, $ -174,680 K
  • 60-Month Beta -1.57
  • Price/Sales 104.47
  • Price/Cash Flow N/A
  • Price/Book 10.02
Trade VIR with:

Options Overview

Details
  • Implied Volatility 224.11%
  • Historical Volatility 123.59%
  • IV Percentile 91%
  • IV Rank 54.69%
  • IV High 341.80% on 03/12/20
  • IV Low 82.04% on 12/10/20
  • Put/Call Vol Ratio 1.07
  • Today's Volume 3,145
  • Volume Avg (30-Day) 1,364
  • Put/Call OI Ratio 1.54
  • Today's Open Interest 8,421
  • Open Int (30-Day) 26,255

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.81
  • Number of Estimates 1
  • High Estimate -0.81
  • Low Estimate -0.81
  • Prior Year -0.71
  • Growth Rate Est. (year over year) -14.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.75 +17.59%
on 02/26/21
83.50 -20.08%
on 02/18/21
+0.28 (+0.42%)
since 02/01/21
3-Month
25.31 +163.65%
on 01/04/21
141.01 -52.68%
on 01/27/21
+35.50 (+113.67%)
since 12/01/20
52-Week
25.31 +163.65%
on 01/04/21
141.01 -52.68%
on 01/27/21
+20.23 (+43.51%)
since 02/28/20

Most Recent Stories

More News
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020.

VIR : 66.73 (+6.55%)
Thinking about trading options or stock in Tandem Diabetes Care, Revolve Group, Callon Petroleum, Vir Biotechnology, or T-Mobile?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNDM, RVLV, CPE, VIR, and TMUS.

TMUS : 123.57 (+3.00%)
TNDM : 95.83 (-0.17%)
VIR : 66.73 (+6.55%)
CPE : 27.09 (+5.94%)
RVLV : 46.66 (+1.21%)
Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza

Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.

JNJ : 159.32 (+0.54%)
SNY : 45.91 (+0.04%)
GSK : 33.73 (+0.36%)
VIR : 66.73 (+6.55%)
Company News for Feb 18, 2021

Companies in the news are: CRL, VIR, LODE, CLPS

CRL : 289.61 (+1.21%)
LODE : 5.28 (-2.40%)
CLPS : 4.71 (-19.76%)
VIR : 66.73 (+6.55%)
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, VZ, NKTR, CVX, and EL.

NKTR : 23.62 (+4.10%)
VIR : 66.73 (+6.55%)
CVX : 102.05 (+2.05%)
EL : 293.95 (+2.83%)
VZ : 55.36 (+0.11%)
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses

- Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza -

VIR : 66.73 (+6.55%)
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2020 on Thursday,...

VIR : 66.73 (+6.55%)
Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod

FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.

LLY : 206.47 (+0.77%)
GSK : 33.73 (+0.36%)
AMGN : 227.04 (+0.94%)
VIR : 66.73 (+6.55%)
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, PFE, AZN, VIR, and ESPR.

AZN : 48.09 (-0.60%)
ESPR : 28.52 (+4.13%)
NKTR : 23.62 (+4.10%)
VIR : 66.73 (+6.55%)
PFE : 33.69 (+0.60%)
Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics

- Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants -

VIR : 66.73 (+6.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 73.43
2nd Resistance Point 70.54
1st Resistance Point 68.63
Last Price 66.73
1st Support Level 63.83
2nd Support Level 60.94
3rd Support Level 59.03

See More

52-Week High 141.01
Fibonacci 61.8% 96.81
Fibonacci 50% 83.16
Fibonacci 38.2% 69.51
Last Price 66.73
52-Week Low 25.31

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar